These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 34368918)

  • 21. Relationship between factor VIII levels and bleeding for rFVIII-SingleChain in severe hemophilia A: A repeated time-to-event analysis.
    Bukkems LH; Jönsson S; Cnossen MH; Karlsson MO; Mathôt RAA;
    CPT Pharmacometrics Syst Pharmacol; 2023 May; 12(5):706-718. PubMed ID: 36965157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.
    Stasyshyn O; Djambas Khayat C; Iosava G; Ong J; Abdul Karim F; Fischer K; Veldman A; Blackman N; St Ledger K; Pabinger I
    J Thromb Haemost; 2017 Apr; 15(4):636-644. PubMed ID: 28166608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic and epidemiological modelling of full-length antihaemophilic factor (recombinant), plasma/albumin-free method, in previously treated patients with haemophilia A : comparison with B-domain deleted rFVIII, and value of potential viral transmission reduction due to plasma/albumin-free status.
    Sclar DA; Evans MA; Skaer TL; Robison LM; Chung KC; Poulios NS
    Drugs R D; 2005; 6(3):149-56. PubMed ID: 15869318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
    Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
    J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching hemophilia A patients to rVIII-SingleChain: The Iberian experience.
    Calvo-Villas JM; Núñez-Vázquez R; Benítez-Hidalgo O; García-Díaz C; Galmés B; Carvalho M; Serrano-Torres P; Aznar-Salatti J; Álvarez-Román MT
    Medicine (Baltimore); 2024 Sep; 103(36):e39255. PubMed ID: 39252288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
    Miners AH; Krishnan S; Pasi KJ
    J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efmoroctocog Alfa: A Review in Haemophilia A.
    Frampton JE
    Drugs; 2016 Sep; 76(13):1281-1291. PubMed ID: 27487799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.
    Tarantino MD; Collins PW; Hay CR; Shapiro AD; Gruppo RA; Berntorp E; Bray GL; Tonetta SA; Schroth PC; Retzios AD; Rogy SS; Sensel MG; Ewenstein BM;
    Haemophilia; 2004 Sep; 10(5):428-37. PubMed ID: 15357767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits.
    Schiavoni M; Napolitano M; Giuffrida G; Coluccia A; Siragusa S; Calafiore V; Lassandro G; Giordano P
    Front Med (Lausanne); 2019; 6():261. PubMed ID: 31850352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe.
    Blatný J; Nielsen EM; Reitzel SB; McMillan AC; Danø A; Bystrická L; Kragh N; Klamroth R
    Haemophilia; 2023 Jul; 29(4):963-974. PubMed ID: 37243934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
    Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
    Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy of simoctocog alfa versus extended half-life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching-adjusted indirect comparison method.
    Kessler CM; Corrales-Medina FF; Mannucci PM; Jiménez-Yuste V; Tarantino MD
    Eur J Haematol; 2023 Nov; 111(5):757-767. PubMed ID: 37587687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
    Gringeri A; Wolfsegger M; Steinitz KN; Reininger AJ
    Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy assessment of a new clotting factor concentrate in haemophilia A patients, including prophylactic treatment.
    Den Uijl I; Mauser-Bunschoten EP; Roosendaal G; Schutgens R; Fischer K
    Haemophilia; 2009 Nov; 15(6):1215-8. PubMed ID: 19686467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials.
    Klamroth R; Wojciechowski P; Aballéa S; Diamand F; Hakimi Z; Nazir J; Abad-Franch L; Lethagen S; Santagostino E; Tarantino MD
    J Blood Med; 2021; 12():115-122. PubMed ID: 33664606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
    Schmidbauer S; Witzel R; Robbel L; Sebastian P; Grammel N; Metzner HJ; Schulte S
    Thromb Res; 2015 Aug; 136(2):388-95. PubMed ID: 26037285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.
    Kragh N; Tytula A; Pochopien M; Aballéa S; Toumi M; Hakimi Z; Nazir J; Bystrická L; Fatoye F
    Eur J Haematol; 2023 Mar; 110(3):262-270. PubMed ID: 36398467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.